Biotechnology US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares rocket 200% to $44.93 by close of trading yesterday, when the company said that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne muscular dystrophy (DMD) patients. 4 October 2012